Cardiovascular (CV) diseases are recognized longterm causes of death after liver transplantation (LT). The objective of this multicenter study was to analyze the prevalence and the evolution of CV risk factors and CV morbidity and mortality in 1819 LT recipients along 5 years after LT. The influence of baseline variables on survival, morbidity, and mortality was studied. There was a continuous and significant increase of the prevalence of all the CV risk factors (except smoking) after LT. CV diseases were the fourth cause of mortality in the 5 years after LT, causing 12% of deaths during the follow-up. Most CV events (39%) occurred in the first year after LT. Preexisting CV risk factors such as age, pre-LT CV events, diabetes, metabolic syndrome, and hyperuricemia, and mycophenolate-free immunosuppressive therapy, increased post-LT CV morbidity and mortality. The development of new-onset CV risk factors after LT, such as dyslipidemia and obesity, independently affected late CV morbidity and mortality. Tacrolimus and steroids increased the risk of posttransplant diabetes, whereas cyclosporine increased the risk of arterial hypertension, dyslipidemia, and metabolic syndrome. In conclusion, CV complications and CV mortality are frequent in LT recipients. Preexisting CV risk factors, immunosuppressive drugs, but also the early new onset of obesity and dyslipidemia after LT play an important role on late CV complications. A strict metabolic control in the immediate post-LT period is advisable for improving CV risk of LT recipients.
(LT) recipients both in the short and long term. (3, 4) Immunosuppressive drugs such as calcineurin inhibitors and steroids contribute to the increase of CV risk in LT recipients. Importantly, in the next years, the prevalence of metabolic syndrome among patients with end-stage liver disease is bound to rise, because nonalcoholic steatohepatitis is a continuously increasing indication for LT in the United States and in Europe. (5) (6) (7) For all these reasons, the impact of CV diseases will become more relevant among candidates for LT in the future, and efforts should be made in order to assess and control the CV risk of candidates for LT.
(5-7) Nevertheless, only a few studies have focused on CV risk factors at the time of LT and their evolution after the surgery, (8, 9) and the predisposing factors for the development of CV diseases in LT recipients have not been extensively studied among large cohorts of patients.
Therefore, the aim of this study was to analyze the prevalence and the evolution of CV risk factors and their impact on CV morbidity and mortality in a large Spanish multicenter series of LT recipients.
Patients and Methods

STUDY DESIGN
This is a prospective multicenter study that enrolled consecutive LT recipients from 15 Spanish transplantation centers between January 2001 and December 2004. Patients who had been previously transplanted or who simultaneously received a nonliver graft were excluded from the study. All patients were followed up every 6 months until 5 years after the transplant or until death. Causes of death were recorded. Survival was calculated from the date of transplantation to the date of death. Patients lost during follow-up were censored at the time of their last visit.
At baseline, the following variables were collected: demographic data, indication of LT, presence of CV risk factors (metabolic syndrome, diabetes, dyslipidemia, arterial hypertension, overweight and obesity, smoking and alcohol consumption), body mass index (BMI), levels of glycosylated hemoglobin, hyperuricemia, presence of renal dysfunction, and previous CV diseases (including ischemic cardiac disease, atrial fibrillation, heart failure, peripheral vasculopathy, and cerebrovascular accident). All these variables, as well as the occurrence of any major CV event (including heart failure, atrial fibrillation, ischemic cardiac disease, stroke, and sudden death) and immunosuppressive, antihypertensive, antidiabetic, and pharmacological treatment for dyslipidemia, were assessed and recorded at each follow-up visit.
DEFINITIONS
Diabetes was defined as a fasting plasma glucose > 126 mg/dL or the need of antidiabetic treatment. (10) Dyslipidemia was defined as total cholesterol >220 mg/dL, triglyceride (TG) >150 mg/dL, or highdensity lipoprotein (HDL) <40 mg/mL in men or <50 mg/mL in women, or the need of specific treatment. Arterial hypertension was defined as systolic blood pressure >139 mm Hg and/or diastolic blood pressure >89 mm Hg or the need of antihypertensive treatment. (11) Hyperuricemia was defined as blood uric acid level >7 mg/dL, or the need of specific treatment. Renal dysfunction was defined as serum creatinine level >1.3 mg/dL. Metabolic syndrome was defined according to the International Diabetes Federation criteria: central obesity (waist circumference of 94 cm for men and of 80 cm for women) plus any 2 of the following 4 factors: raised TG level (150 mg/dL, or specific treatment for hypertriglyceridemia); reduced HDL cholesterol (<40 mg/dL in males and < 50 mg/dL in females, or specific treatment for this lipid abnormality); raised blood pressure (systolic blood pressure 130 or diastolic blood pressure 85 mm Hg, or treatment of previously diagnosed hypertension); raised fasting plasma glucose (FPG; 100 mg/dL, or previously diagnosed diabetes). (13) When the waist circumference was not available, the BMI > 30 kg/m 2 was used as surrogate of central obesity.
ETHICS
The Ethics Committee of Navarra (Spain) approved the study protocol. According to the national law, the study was evaluated by the Spanish Agency of Medicines and Medical Devices.
STATISTICAL ANALYSIS
The prevalence of CV risk factors was analyzed at baseline and during the follow-up. Differences in the frequency of CV risk factors at different times in the study were analyzed by using nonparametric tests (Mann-Whitney U and Friedman test for independent and paired variables, respectively) for quantitative variables without normal distribution and with parametric test (t test) for quantitative variables with a normal distribution. Differences in the frequency of categorical variables among different groups were compared using chi-square and Fisher's test. The predisposing baseline factors of developing new-onset CV risk factors were analyzed by using logistic regression analysis.
Survival was calculated using the Kaplan-Meier method. We performed univariate regression analysis to assess the influence of different variables (including the etiology of liver disease, baseline CV risk factors, and immunosuppressive drugs) on the occurrence of new major CV events (atrial fibrillation, heart failure, ischemic cardiopathy, cerebrovascular accident, and sudden death), death, and death of CV origin. CV events and deaths were defined as perioperative (in the first 30 days after LT), early (within 12 months after LT), and late (beyond 12 months after LT) in order to assess the differential impact of the clinical characteristics of the patients on CV morbidity and mortality at short and long term. The following baseline variables were included in the univariate analysis as categorical variables: recipient and donor sex, indication for LT, presence of viral hepatitis or hepatocellular carcinoma (HCC), diabetes, need for insulin therapy, dyslipidemia, arterial hypertension, hyperuricemia, overweight or obesity, smoking and alcohol consumption, renal failure, previous CV diseases, new-onset diabetes, dyslipidemia, obesity, and arterial hypertension 1 year after LT. Recipient and donor's age, baseline creatinine, bilirubin, hemoglobin, albumin, glycosylated hemoglobin, time of cold ischemia, and BMI were included as continuous variables. Variables with statistical significance at the P < 0.20 level in the univariate analysis were entered into a multivariate regression model using a stepwise selection method (forward conditional). A P value < 0.05 was considered as statistically significant. Software SPSS 20.0 (SPSS Inc., Chicago, IL) was used to perform all statistical analysis. 
Results
BASELINE CHARACTERISTICS AND CV RISK FACTORS
A total of 1819 liver transplant recipients entered the study. The majority of patients had alcoholic or hepatitis C virus (HCV)-related liver cirrhosis. The prevalence of HCC among the entire population was 25.5% (Table 1) . CV risk factors and complications at the time of transplantation are shown in Table 1 . Nearly half of the patients were smokers or ex-smokers and overweight or obese. There was also a high prevalence of insulin-dependent diabetes. However, prevalence of arterial hypertension and dyslipidemia were relatively low. Approximately 5% of patients had a previous history of major CV diseases, including ischemic cardiopathy, peripheral vascular diseases, and cerebrovascular accidents. The prevalence rates of renal dysfunction and hyperuricemia were approximately 15%.
CV RISK FACTORS AFTER LT
There was a continuous and significant increase of the prevalence of arterial hypertension, diabetes, dyslipidemia, and obesity starting at 6 months after LT.
The only CV risk factor that decreased after transplantation was tobacco smoking (Fig. 1) . Renal dysfunction and hyperuricemia also increased along the follow-up (41% and 43% at 5 years, respectively). Furthermore, the control of CV risk factors was more challenging over time: the proportion of patients requiring 2 or more drugs to control arterial hypertension increased from 7% at 6 months to 20% at 5 years after transplantation, and the proportion of patients requiring statin treatment increased from 2% at 6 months to 7% at 5 years after transplantation. Patients requiring insulintherapy to control diabetes was 12% at 6 months and 21% at the end of follow-up. There was a progressive increase of BMI and serum levels of cholesterol, glucose, uric acid, and creatinine from the time of transplantation until the end of the follow-up (Supporting Table 1 ).
Baseline predictors of developing de novo CV risk factors 1 year after LT were investigated. Patients transplanted because of alcoholic liver disease showed higher risk of developing de novo metabolic syndrome (hazard ratio [HR], 1.90; 95% CI, 1.41-2.55; P < 0.001), arterial hypertension (HR, 1.37; 95% CI, 1.37-1.08; P 5 0.008), obesity (HR, 1.89; 95% CI, 1.18-3.04; P 5 0.008), and dyslipidemia (HR, 1.43; 95% CI, 1.11-1.85; P 5 0.005) compared with patients transplanted for other indications. The impact of the immunosuppressive regimen on the new-onset CV risk factors was also evaluated and confirmed that different types of immunosuppressive regimens differently affect the development of new-onset CV risk factors 1 year after LT. In particular, patients receiving cyclosporine were at a higher risk of developing metabolic syndrome (HR, 2.13; 95% CI, 1.65-2.75; P < 0.001), arterial hypertension (HR, 2.13; 95% CI, 1.70-2.66; P < 0.001), and de novo dyslipidemia (HR, 1.94; 95% CI, 1.54-2.45; P < 0.001) as compared with patients treated with tacrolimus. Conversely, cyclosporine therapy was associated with a reduced risk of de novo diabetes compared with tacrolimus therapy (HR, 2.25; 95% CI, 1.80-3.61; P < 0.001), whereas steroids also increased the risk of de novo diabetes (HR, 1.87; 95% CI, 1.09-3.20; P 5 0.02). A complete description of the independent predictors of de novo CV risk factors is provided in Supporting Table 2 .
SURVIVAL ANALYSIS AND MORTALITY
In the first 5 years after LT, 437 patients died. The 1-, 3-, and 5-year actuarial survival rates of the study population were 88%, 80%, and 76%, respectively (Fig. 2) . Perioperative mortality (within the first 30 days after LT) was 4%. The main causes of perioperative mortality were CV diseases (28%), nonhepatic infectious diseases (26%), hepatic diseases (12%), and renal failure (4%). Interestingly, we did not observe any significant association between previous history of CV disease and perioperative mortality. Only 1 out of the 76 patients who died in the first 30 days after LT had previous history of CV diseases. The only clinical characteristic associated with perioperative mortality was renal dysfunction that was present in 28% of the patients who died in the first 30 days after LT versus 13% in patients who survived more than 30 days (P 5 0.001). The relative risk of 30-day mortality associated with renal failure was 2.15 (HR, 2.15; 95% CI, 1.25-3.70; P 5 0.005).
Along the 5 years of follow-up, the main causes of death were liver disease (27%), de novo malignant tumors (18%), infectious diseases (17%), CV diseases (12%), and renal failure (2%). Multivariate analysis showed that HCV infection, diabetes, hyperuricemia, renal dysfunction, and previous history of CV disease at baseline were independent predictors of mortality. Patients on a tacrolimus-based immunosuppressive regimen had lower mortality risk compared with patients treated with cyclosporine. Regarding donor data, the mortality risk increased with the increasing age of the donors (Table 2 ). Figure 3 displays the effect of pre-LT CV events on the 5-year overall survival. As shown in Supporting Fig. 1 , patients who had pre-LT heart failure showed a significantly lower survival compared with patients with no pre-LT CV events (P < 0.001). The unadjusted relative risk of 5-year mortality for patients with pre-LT heart failure was 3.06 (95% CI, 1.68-5.58; P < 0.001) compared with patients with no pre-LT CV events.
CV MORBIDITY AND RISK FACTORS
There were 186 patients who suffered 250 major CV events (including myocardial infarction, cerebrovascular accident, atrial fibrillation, congestive heart failure, or sudden cardiac death) during the first 5 years after LT and 53 patients died because of a CV event. Interestingly, 24% of the CV events occurred in the first 30 days after LT and approximately one-third occurred in the first year after LT, representing 39% of the total CV events observed in the follow-up (Fig. 4) . Among early CV events (within 12 months after LT), most of them were cardiac (74%), followed by cerebrovascular accidents (23%) and sudden death (3%). The distribution of late CV events (beyond 12 months after LT) was similar to the early CV events. Cardiac diseases represented the majority of late CV events (81%), followed by cerebrovascular accidents (16%) and sudden cardiac death (2%). Considering all CV events, specific clinical characteristics such as older age, higher BMI, arterial hypertension, metabolic syndrome, hyperuricemia, and pre-LT alcoholic liver disease were associated with the occurrence of CV events after LT. As expected, previous CV diseases were significantly associated with CV events after LT, and this association was particularly strong for pre-LT cerebrovascular accidents and atrial fibrillation (Table 3) . Notably, in this series, previous CV diseases were not significantly associated with perioperative CV morbidity. A total of 7 out of 61 (11.5%) patients who experienced CV events in the first 30 days after LT had a pretransplant history of CV diseases, compared with 115 (6.5%) of patients without perioperative CV events (P 5 0.13). We did not find any significant association between baseline clinical variables and perioperative CV events. Older age minimally increased the perioperative CV morbidity among this population (HR, 1.03; 95% CI, 1.0-1.06; P 5 0.04).
Multivariate analysis showed that older age at transplantation and history of a CV event before LT were independent risk factors for both early and late CV events, whereas a mycophenolate mofetil (MMF)-free immunosuppression and hyperuricemia were independent risk factors for late CV events ( Table 4) .
The role of new-onset CV risk factors in predicting a late CV event was further investigated, revealing that the strongest independent predictor of late CV events was new-onset dyslipidemia (Table 4) .
CV MORTALITY
A total of 53 patients died as consequence of CV diseases during the 5 years after LT. As observed for the global CV events, almost half of the CV deaths (21 patients, 40%) occurred within the first month after LT and most of them occurred in the first year after the surgery (33 patients, 62%; Fig. 4 ). Main causes for early CV deaths were cardiac disease (67%), cerebrovascular accidents (24%), and sudden death (9%).
Coronary artery disease caused the majority of the CV deaths in the first year after transplantation. Globally, CV diseases accounted for 28% of deaths in the first 30 days after LT, 15% in the first year after LT, and 12% of the deaths in the 5 years of follow-up. The 1-and 5-year CV mortality rates were 1.7% and 2.9%, respectively. We did not find any significant association between pre-LT CV events and perioperative CV mortality. Indeed, only 1 out of the 21 (5%) patients who died because of CV diseases in the perioperative period had a history of pre-LT CV diseases and died because of a cerebrovascular accident. Patients who died because of CV diseases in the first 30 days after LT showed higher prevalence of diabetes (43% versus 22%; P 5 0.02) and hyperuricemia (38% versus 16%; P 5 0.01) compared with the rest of the population. Diabetes and hyperuricemia were the only 2 independent predictors of perioperative CV mortality (diabetes-HR, 2.6; 95% CI, 1.0-6.2; P 5 0.03; hyperuricemia-HR, 3.1; 95% CI, 1.3-7.7; P 5 0.01). Considering the first 12 months after LT, diabetes, hyperuricemia, and a MMF-free immunosuppressive regimen were found to be independent predictors of early CV death, whereas corticosteroid therapy was surprisingly related to a lower risk of CV death ( Table  5) . History of previous CV diseases was the only pretransplant independent predictor of late CV mortality (Table 5 ). Regarding the effect of new-onset CV risk factors on predicting late CV mortality, we found that, regardless the presence of other risk factors, patients with new-onset obesity had a 3.5-fold increased risk of late CV mortality compared with the patients who did not develop obesity.
Discussion
In the past, patients with cirrhosis were regarded as a low-risk population for CV disease, especially due to the nutritional impairment and hemodynamic changes associated with liver dysfunction. (1, 14, 15) However, in the latest decades, this paradigm has changed and the role of CV risk among candidates for LT has taken more relevance. (2, 16, 17) CV risk is especially high in patients with nonalcoholic fatty liver disease, (18) which has become an increasingly indication for LT. (7, 19) Regardless the indication, this study supports the importance of CV diseases in determining morbidity and mortality after LT, and corroborates previous reports showing that the control of CV risk factors after LT may be complex especially in specific subgroups of patients. Importantly, this work discloses that a poor control of the CV risk factors from the early stages after LT has substantial consequences in the morbidity and mortality after LT.
As previously described, (4) CV diseases accounted for the fourth cause of death among liver recipients in this series and for the first cause of perioperative mortality, causing 28% of the deaths that occurred in the first 30 days after LT. Globally, most of the CV events, including the fatal events, occurred in the first year after LT, suggesting that preexisting conditions may play a major role in determining the CV morbidity and mortality among this population. Indeed, in this large national series of candidates for LT, the prevalence of CV risk factors was relatively high. Particularly, there was a high prevalence of obesity and diabetes (particularly insulin-dependent), whereas, as expected among patients with cirrhosis, the prevalence of dyslipidemia and arterial hypertension were relatively low. Preexisting CV risk factors affect overall survival and CV mortality and morbidity in the 5 years after LT. Older age at the time of LT, prior history of CV diseases, preexisting hyperuricemia, and diabetes have an important impact on the prognosis after LT both in terms of overall survival and CV morbidity and mortality. Interestingly, we found that the strongest predictors of perioperative CV mortality were diabetes and hyperuricemia, whereas the effect of preexisting CV diseases became evident only at more advanced postoperative stages, namely, from 1 year after LT. We also found that pre-LT cerebrovascular accidents and atrial fibrillation were strongly associated with post-LT CV events. In this series, the unadjusted risk increases of post-LT CV events for patients with pre-LT cerebrovascular accidents and atrial fibrillation were 7.9 and 6.5, respectively (data not shown), suggesting that these 2 pre-LT clinical conditions may require a special consideration while evaluating the CV risk of candidates for LT. Pre-LT CV complications negatively influenced the overall survival and, considering the different types of CV complications, a history of heart failure had the most relevant influence on overall survival with an unadjusted increased risk of death of 3-fold compared with patients with no pre-LT CV events. However, the small number of patients with these pre-LT CV events among the entire study population (26 patients had pre-LT cerebrovascular events, 34 patients had pre-LT atrial fibrillation, and 21 had pre-LT heart failure) does not allow this study to draw definitive conclusions for considering a specific type of pre-LT CV complications as an exclusion criteria for LT, and further studies are needed to corroborate this finding. Age and diabetes are recognized predictors of coronary artery disease after LT. (16) However, this is the first study in which pre-LT hyperuricemia is identified as a strong independent predictor of CV diseases among LT recipients. Among the general population, hyperuricemia is a recognized risk factor for CV events, including heart failure, and CV mortality, (20) (21) (22) (23) and importantly, uric acid-lowering agents have been shown to improve CV dysfunction and decrease the CV risk in the general population. (24) (25) (26) This should be taken into account at the time of CV risk evaluation of candidates for LT and in the posttransplant management.
Another important finding of this study is that all the CV risk factors assessed, except tobacco use, showed a continuous increase during the follow-up that is evident since the first 6 months after LT. Notably, in accordance with other reports, the control of diabetes, dyslipidemia, and arterial hypertension worsened during the 5 years after LT. (27, 28) Despite the relatively short follow-up of this series that may not allow us to fully capture the longterm impact of the newonset CV risk factors on late CV morbidity, this study revealed that the development of new-onset CV risk factors may modify the CV risk in the first 5 years after transplantation. Specifically, patients who developed new-onset obesity had a 3.5-fold increased risk of late CV mortality compared with patients who did not gain weight. These findings underline the importance of weight and metabolic control since the early stages after LT, in order to reduce the CV morbidity and mortality of liver recipients.
Many factors could be advocated for explaining the worsening of metabolic profile after LT, mainly the healing of liver cirrhosis and the use of immunosuppressive drugs. Specific clinical characteristics could also predispose some of these patients to develop the components of metabolic syndrome. Actually, in this series, patients transplanted because of alcoholic liver disease had the highest risk to develop new-onset CV risk factors such as metabolic syndrome, arterial hypertension, obesity, and dyslipidemia, suggesting that these patients probably require a more strict metabolic control since the early stages after LT.
The potential influence of immunosuppressive drugs on the morbidity and mortality after LT deserves a detailed comment since these drugs may affect the longterm outcome after LT in different ways: by their effect on renal function, by their effect on glucose and fat metabolism, and by increasing the risk of malignancies. In the present series, as reported previously, tacrolimus-based therapy was associated with a better overall survival compared with cyclosporine-based therapy. (29) Many reasons can underlie this finding. First, it may be related to a lower incidence of acute rejection found in patients treated with tacrolimus, and second, it can be the consequence of its better profile on renal function, blood pressure, and serum lipid levels compared with clyclosporine. (30) Indeed, in this series, patients receiving a cyclosporine-based immunosuppressive regimen showed an increased risk of developing new-onset arterial hypertension, dyslipidemia, and metabolic syndrome. On the contrary, cyclosporine, as previously reported, showed a more favorable impact on glycemic control compared with tacrolimus. (29) As described elsewhere, also in this series, a steroid-free immunosuppression regimen has been shown to be safe and reduce early development of metabolic complications such as diabetes. (31) Patients who received a MMF-containing immunosuppressive therapy had a lower risk of late CV morbidity and early CV mortality. MMF can be used to avoid steroids in the immediate postoperative period and to reduce, delay, or even withdraw calcineurin inhibitors in different phases after LT, thus improving the control of arterial hypertension, dyslipidemia, and renal dysfunction in the long term. (32, 33) In a recent article, the use of a steroid-free regimen with tacrolimus and MMF was associated with a trend toward better preservation of kidney function and reduction of CV risk score without increasing the risk of rejection. (34) To conclude, this study shows that the prevalence of the components of metabolic syndrome among candidates for LT is high and that these patients are a highrisk population for CV events due to preoperative and postoperative factors. Diabetes, hyperuricemia, and obesity before LT, but also new-onset dyslipidemia and obesity, could contribute to enhance this risk, especially among those patients who had a previous history of CV diseases. According to our results, we suggest that older patients; patients with hyperuricemia, diabetes, and obesity before LT; and those transplanted because of alcoholic liver disease deserve a more careful multidisciplinary CV and metabolic evaluation. Further studies should evaluate the effect of uric acid-lowering agents on the short-term and longterm outcome of LT. Different immunosuppressive drugs have specific effects on CV risk factors and CV morbidity and mortality. Particularly, steroid-free and/or immunosuppressive regimens including MMF may be associated with lower CV morbidity and mortality and therefore MMF should be considered in order to reduce or prevent the use of steroids after LT. Regarding calcineurin inhibitors, the results of this study, in accordance with the literature, suggest that tacrolimus should be considered as a first-line calcineurin inhibitor in LT recipients because it reduces the risk of de novo arterial hypertension and dyslipidemia and is associated with a better overall survival compared with cyclosporine. This is particularly relevant especially after considering that the worsening of metabolic profile, ie, the new onset of obesity and dyslipidemia after LT, independently increases the risk of CV morbidity and mortality among LT recipients. In contrast, in patients with a higher risk of diabetes, cyclosporine should be regarded as a first-line calcineurin inhibitor, since it is associated with a reduced risk of de novo diabetes after LT. A careful evaluation of the metabolic profile of candidates for LT and the use of immunosuppressive therapies aimed to improve the different components of metabolic syndrome should be ensured.
